APAC Type 2 Diabetes Mellitus Therapeutics Market Analysed & Forecast by GBI Research in Its Report Published at MarketPublishers.com
26 Feb 2016 • by Natalie Aster
LONDON – Type 2 diabetes mellitus (T2DM) holds the largest share (around 85-95%) of diabetes mellitus patients worldwide. During the past decade, the T2DM treatment has been considerably revolutionised with the increased usage of novel therapies and treatment options.
The list of currently marketed products includes biguanide (metformin), thiazolidinediones, sulfonylureas, DPP-4 inhibitor, GLP-1 receptor agonist, insulin therapies and SGLT-2 inhibitor, among others. However, the T2DM treatment market is experiencing a shortage of products that provide better glycemic control, prevent and cure various diabetic complications like retinopathy, cardiovascular disease and diabetic nephropathy.
Meantime, the APAC T2DM therapeutics market contains new advanced products such as Galvus - a DPP-4 inhibitor, Victoza - a GLP-1 receptor agonist and Jardiance - a SGLT-2 inhibitor. Through 2021, the value of the APAC T2DM therapeutics market is set to exceed USD 10.2 billion mark, growing at a 7.75 CAGR in the years ahead.
Insightful report “Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets” comprises valuable data useful for understanding of the clinical context of T2DM therapeutics in APAC. The research study offers data on symptoms, etiology, pathophysiology, epidemiology, diagnosis and treatment options of T2DM. The report discusses the current and latest therapeutic strategies and products, reviews companies dominating the marketplace and also identifies the top market opportunities and identifies potential risks of novel medicines adoption in T2DM treatment. Furthermore, this research report lays special emphasis on the market growth drivers and highlights major challenges. Granular forecasts for the APAC T2DM therapeutics market as well as for T2DM therapeutics markets in China, India, Australia, and Japan are available here, too.
Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
Published: January, 2016
Price: US$ 4,995.00
More reports created by the publisher can be found at GBI Research page.